2023
Cellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchMeSH KeywordsGraft RejectionHumansImmune ToleranceImmunosuppression TherapyTransplantation, HomologousVascularized Composite AllotransplantationConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell types
2020
Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review
Safi AF, Kauke M, Nelms L, Palmer WJ, Tchiloemba B, Kollar B, Haug V, Pomahač B. Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 327-335. PMID: 33229219, DOI: 10.1016/j.bjps.2020.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsRatsSwineTacrolimusTreatment OutcomeVascularized Composite AllotransplantationConceptsLocal immunosuppressionSystematic reviewAllograft survivalComposite allotransplantationAllograft survival dataCell-based therapy strategiesImproved allograft survivalMain immunosuppressive agentMeta-Analyses (PRISMA) guidelinesPreclinical animal studiesPreferred Reporting ItemsMalignant side effectsImmunosuppressive agentsPreclinical dataSignificant prolongationRat modelHuman trialsExclusion criteriaImmunosuppressionSide effectsAnimal studiesReporting ItemsPubMed databaseSystemic toxicityTherapy strategies
2019
Five-Year Follow-up after Face Transplantation
Tasigiorgos S, Kollar B, Turk M, Perry B, Alhefzi M, Kiwanuka H, Nizzi M, Marty F, Chandraker A, Tullius S, Riella L, Pomahac B. Five-Year Follow-up after Face Transplantation. New England Journal Of Medicine 2019, 380: 2579-2581. PMID: 31141626, DOI: 10.1056/nejmc1810468.Peer-Reviewed Original ResearchMeSH KeywordsAdultFaceFacial TransplantationFollow-Up StudiesGraft RejectionHumansImmunosuppression TherapyInfectionsMiddle AgedPostoperative Complications
2015
Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration
Kueckelhaus M, Fischer S, Seyda M, Bueno E, Aycart M, Alhefzi M, ElKhal A, Pomahac B, Tullius S. Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Transplant International 2015, 29: 655-662. PMID: 26265179, PMCID: PMC4785085, DOI: 10.1111/tri.12652.Peer-Reviewed Original ResearchConceptsAcute rejectionImproved long-term graft outcomesLong-term graft outcomeChronic allograft deteriorationCytomegalovirus infection statusGraft preservation techniquesUpper extremity transplantationUpper extremity transplantsAntibody-mediated rejectionGood midterm resultsSpecific treatment strategiesAllograft deteriorationChronic rejectionClinical VCAVCA graftsGraft outcomeImmunosuppressive strategiesLocal immunosuppressionMidterm resultsExtremity transplantationCell-based therapiesHLA matchingTolerance inductionTreatment strategiesUS CentersInitial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation
Diaz-Siso J, Fischer S, Sisk G, Bueno E, Kueckelhaus M, Talbot S, Carty M, Treister N, Marty F, Milford E, Pomahac B, Tullius S. Initial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation. American Journal Of Transplantation 2015, 15: 1421-1431. PMID: 25777324, DOI: 10.1111/ajt.13103.Peer-Reviewed Original ResearchConceptsAcute rejectionVCA recipientsMaintenance immunosuppressionSteroid-resistant acute rejectionLate acute rejectionSolid organ transplantationComposite tissue allotransplantationMaintenance steroidsTopical immunosuppressionCurrent immunosuppressionSteroid withdrawalBolus treatmentOrgan transplantationLow doseImmunosuppressionTissue allotransplantationInitial experienceFurther experienceSteroidsRecipientsTacrolimusPatientsTreatmentMonthsLow levels
2014
Fortschritte in der Gesichtstransplantation
Kueckelhaus M, Lehnhardt M, Fischer S, Eriksson E, Pomahac B, Hirsch T. Fortschritte in der Gesichtstransplantation. Handchirurgie · Mikrochirurgie · Plastische Chirurgie 2014, 46: 206-213. PMID: 25162238, DOI: 10.1055/s-0034-1385850.Peer-Reviewed Original ResearchMeSH KeywordsEstheticsFacial TransplantationForecastingGermanyHumansImmunosuppression TherapyMicrosurgeryOrgan PreservationPatient SelectionSkin TransplantationConceptsVascularised composite allotransplantationFace transplantationLife-threatening side effectsSolid organ transplantationDifferent transplant centersImmunosuppressive regimensMaintenance immunosuppressionVCA proceduresImmunosuppressive strategiesTransplant centersPatients' qualityLifelong immunosuppressionOrgan preservationSurgical techniqueOrgan transplantationComposite allograftsComposite allotransplantationSide effectsTransplantationFunctional reintegrationImmunosuppressionAnatomic structuresImmunogenic partFirst caseDifferent protocolsFacial and Hand Allotransplantation
Pomahac B, Gobble R, Schneeberger S. Facial and Hand Allotransplantation. Cold Spring Harbor Perspectives In Medicine 2014, 4: a015651. PMID: 24478387, PMCID: PMC3935393, DOI: 10.1101/cshperspect.a015651.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationFacial transplantationLong-term immunosuppressionMinimization of immunosuppressionGood functional outcomeTreatment of patientsMultidisciplinary team approachNovel therapeutic optionsSevere facial disfigurementAllograft survivalHand allotransplantationSkin rejectionTherapeutic optionsFunctional outcomeLimb lossComposite allotransplantationSide effectsTeam approachTransplantationSurgical planningFacial disfigurementImmunosuppressionAllotransplantationComplex proceduresPatients
2013
Facial allotransplantation: A 3-year follow-up report
Diaz-Siso J, Parker M, Bueno E, Sisk G, Pribaz J, Eriksson E, Annino D, Tullius S, Pomahac B. Facial allotransplantation: A 3-year follow-up report. Journal Of Plastic Reconstructive & Aesthetic Surgery 2013, 66: 1458-1463. PMID: 23911716, DOI: 10.1016/j.bjps.2013.06.046.Peer-Reviewed Original ResearchMeSH KeywordsAllograftsFaceFacial InjuriesFacial TransplantationFollow-Up StudiesHumansImmunosuppression TherapyMaleMuscle, SkeletalQuality of LifeRecovery of FunctionThermosensingTouchConceptsQuality of lifeFunctional recoveryFace transplantationFirst postoperative yearPatients' functional recoveryPost-operative monthHigh-voltage burnsSatisfactory aesthetic resultsFace transplant patientsSevere facial defectsImmunosuppression dosesSteroid therapyPostoperative yearTransplant patientsMale patientsNormal sensationImmunologic complicationsWomen's HospitalMotor functionSurgical techniquePatient reportsReconstructive surgeryClose monitoringMultidisciplinary teamOccupational therapy
2011
Establishing a Composite Tissue Allotransplantation Program
Pomahac B. Establishing a Composite Tissue Allotransplantation Program. Journal Of Reconstructive Microsurgery 2011, 28: 03-06. PMID: 21811966, DOI: 10.1055/s-0031-1285823.Peer-Reviewed Original ResearchConceptsComposite tissue allotransplantationPromising surgical optionPotential patient safety issuesLife-long immunosuppressionPatient safety issuesClinical research interestInstitutional review boardSurgical optionsPostoperative costsWomen's HospitalTissue allotransplantationMultidisciplinary teamMedical careCTA programReview boardHospital administrationLogistic hurdlesMedical insuranceHospitalAdministrationUnited StatesSafety issuesImmunosuppressionPatientsAllotransplantation
2008
Facial Transplantation and Immunosuppressed Patients: A New Frontier in Reconstructive Surgery
Pomahac B, Aflaki P, Chandraker A, Pribaz J. Facial Transplantation and Immunosuppressed Patients: A New Frontier in Reconstructive Surgery. Transplantation 2008, 85: 1693-1697. PMID: 18580458, DOI: 10.1097/tp.0b013e318176b29e.Peer-Reviewed Original ResearchMeSH KeywordsFacial TransplantationHumansImmunosuppression TherapyPatient SelectionSurgery, PlasticTransplantation ImmunologyConceptsPartial face transplantationOrgan transplant recipientsFace transplantationTransplant recipientsLife-long immunosuppressionPatient selection criteriaRisk of malignancyComposite tissue transplantationFacial transplantationAlternative reconstructive methodImmunosuppressive regimenImmunosuppressive therapyAdditional immunosuppressionSurgical resectionImmunosuppressed patientsOrgan recipientsPatient populationWomen's HospitalReconstructive surgeryTransplantationIRB approvalSkin cancerReconstructive methodsControversial procedureTissue transplantation